Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312

version: 26; Last updated: 2025-08-18 13:22:42+0000

Profile: NonComparativeEvidence

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/367926

identifier: FEvIR Object Identifier/367926, FEvIR Linking Identifier/NCT03640312-secondaryOutcomeMeasure-8--OG001

name: NCT03640312_secondaryOutcomeMeasure_8_OG001

title: Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312

citeAs:

Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367926. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367926. Computable resource at: https://fevir.net/resources/Evidence/367926#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Candesartan

note: ,

Outcome Measure Population Description: Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)

variableDefinition

variableRole: Outcome

observed: Change in Mean Systolic Blood Pressure at 6 weeks - (NCT03640312)

statistic

statisticType: Least Squares Mean

quantity: -10.87 mm Hg

SampleSizes

-KnownDataCount
*30

AttributeEstimates

-TypeRange
*95% Confidence Interval-15.24--6.5 mm Hg